| Type | Public |
|---|---|
| Traded as | LSE: RENE |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
| Website | reneuron.com |
ReNeuron (LSE: RENE) is a UK-based stem cell research company, whose shares are listed on the Alternative Investment Market. Its focus is on the development of stem cell therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases.
ReNeuron is currently testing the effects of neural stem cells on spines for neuroregeneration.[1] They are also testing the use of fetal stem cells on stroke patients.[2]